Dr. Christopher Lock, M.D. Ph.D.

diagnose early Advisor & Ms Clinical Lead At Stanford

Education

  • King’s College, University of London

  • Westminster Hospital Medical School, University of London, Entrance Scholarship, MD

  • Imperial Cancer Research Fund Laboratories, Guy’s and King’s College

  • Hospital, University of London, PhD

  • Internal Medicine / Neurology Jul.1993-Jun.1997 Stanford University Medical Center

  • Neuroimmunology Fellow / Clinical Instructor Jul.1997-Jun.2000 Department of Neurology, Stanford Supervisor: Dr. Larry Steinman Funding: National Multiple Sclerosis Society

Dr. Christopher Lock has dedicated his career to understanding the basic science underlying Multiple Sclerosis and to caring for patients with Multiple Sclerosis. Over a career of more than twenty years at Stanford University and the Palo Alto Medical Foundation as a clinician and basic science researcher, Dr. Lock has published in prestigious journals such as the Nature Medicine, taught medical students and neurology residents and fellows, worked at a pharmaceutical start-up, and has been an investigator on multiple grants focused on both treatment and the basic science of Multiple Sclerosis.

  • Sutter Neuroscience Research Consortium 2014-2015

  • Peninsula Coastal Lead Neuroscience Research Advisory Board 2014-2015

  • Sutter Health, East Bay Neuroscience Institute Clinical Research Sites for the Network of Excellence in 2011

  • Neuroscience Clinical Trials (NEXT sites) (U10) NINDS Project Grant Application, Principle Investigator Sutter Health Data and Safety Monitoring Board (DSMB) 2009

  • Rituximab - neuromyelitis optica (NMO) study Dr. Bruce Cree, Chairperson, UCSF

  • Carantech Biosciences, Inc. 2006-2008 Founder: Dr. Claude Genain Multiple sclerosis drug and biomarker development Lead molecule at early pre-clinical stage of development Responsible for planning and conduct of scientific research, development of expression and purification methods, testing in EAE model. Planning and discussion of cGMP production, toxicology studies, and other requirements for IND application. Presentations to VCs and Angel investors.